| Methods |
26‐week, double‐blind, placebo‐controlled study |
| Participants |
People with type 2 diabetes inadequately controlled with insulin alone or combined with metformin |
| Interventions |
Participants received alogliptin 12.5 mg (n = 131), alogliptin 25 mg (n = 129) or placebo (n = 130) once daily, as add‐on to stable insulin therapy with or without metformin |
| Outcomes |
HbA1c, body weight, hypoglycaemia, incidences of overall adverse events, and of gastrointestinal, dermatological and infection‐related events |
| Notes |
Need to determine whether subgroup analysis for insulin monotherapy group is possible |
